Aug. 17 at 12:13 AM
$NVCR
Surface-level algorithms treat Novocure like a static glioblastoma play, completely missing the multi-front commercial expansion unfolding over the next 6–24 months:
• Torso Oncology Monopoly: Expanding from niche GBM into massive TAMs with Optune Pax® (pancreatic cancer) and Optune Lua® (NSCLC).
• Near-Term Tsunami: METIS brain-mets PMA filing and lighter, next-gen array adoption driving higher daily adherence hours.
• Financial Turning Point:
$183.6M Q2 '26 rev (+16% YoY), positive Adjusted EBITDA (
$10.8M), and a
$440M+ cash chest—dilution fear is dead.
You won't recognize
$NVCR 18 months from now when multi-indication revenue explodes! 🧬💎
